Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subject has provided informed consent prior to initiation of any study specific activities/procedures.~* Male or female subject is 18 years of age or older at time of signing the informed consent form.~* Subject has a diagnosis of RA or PsA and indicated for treatment with etanercept per the current label, based on investigator judgment.~* Subject is naïve to etanercept.~* Subject is able to self-inject etanercept.~Exclusion Criteria~* Subject is diagnosed with Felty's syndrome.~* Subject has active erythrodermic, pustular, guttate psoriasis, or medication induced psoriasis, or other skin conditions.~* Subject has a history of clinically significant skin allergies~* Subject has a history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes.~* Subject has any active infection for which anti-infectives were indicated within 4 weeks prior to screening.~* Subject has had a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to first dose of investigational product.~* Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening.~* Subject has known alcohol addiction or dependency.~* Subject has positive hepatitis B surface antigen, hepatitis B core antibody (confirmed by hepatitis B virus deoxyribonucleic acid (DNA) test) or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. (Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll).~* Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma.~* Subject has known history of active tuberculosis.~* Subject has used biologic disease modifying agent (DMARD) less than or equal to 3 months prior to screening.~* If subject is receiving continuous treatment with acetaminophen, non-steroidal anti-inflammatory drug or tramadol, hydrocodone, oxycodone, codeine, and/or propoxyphene and the dose is within 4 hours before study visit and dose is not stable for ≥ 2 weeks before first dose of investigational product~* For subjects not on continuous analgesics, subject has taken the following within 4 hours before screening: acetaminophen, non-steroidal anti-inflammatory drugs, hydrocodone, codeine, tramadol, propoxyphene, and/or oxycodone (unless in the form of OxyContin). For subjects not on continuous analgesics, subject has taken OxyContin within 24 hours before screening.~* Subject has received live vaccines less than or equal to 4 weeks prior to first dose of investigational product.~* Subject has laboratory abnormalities during screening.~* Estimated creatinine clearance less than 50 mL/min.~* Subject has any other laboratory abnormality, which, in the opinion of the investigator poses a safety risk, will prevent the subject from completing the study, or will interfere with the interpretation of the study results.~* Subject is currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s).~* Other investigational procedures while participating in this study.~* Women who are pregnant or breastfeeding, or planning to become pregnant or breastfeed during treatment and/or within 4 weeks after the last dose of etanercept.~* Women of child-bearing potential with a positive pregnancy test.~* Women of child-bearing potential who are unwilling to practice true sexual abstinence or unwilling to use 1 of the following effective birth control methods during treatment and for an additional 4 weeks after the last dose of etanercept.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence AB (Type: EXPERIMENTAL): Participants received a single 50 mg subcutaneous (SC) dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 1 (Treatment A) followed by a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 8 (Treatment B).
- Sequence BA (Type: EXPERIMENTAL): Participants received a single 50 mg SC dose of the new formulation of etanercept in a prefilled SureClick autoinjector on day 1 (Treatment B) followed by a single 50 mg SC dose of the commercial formulation etanercept in a prefilled SureClick autoinjector on day 8 (Treatment A).

Based on this trial design, predict the completion outcome and termination type (if applicable).